Search Results

Ferring Pharmaceuticals announced that its clinical development partner, Seikagaku Corporation, achieved positive topline results for its registrational Phase 3 clinical trial of SI-6603, an investigational treatment for lumbar disc herniation.

Ferring Pharmaceuticals and its clinical development partner, Seikagaku Corporation (Seikagaku), today announced the presentation of data looking at the efficacy and safety profile of SI-6603 (generic name: condoliase), an investigational product intended to treat radicular leg pain associated with lumbar disc herniation (LDH).

Spineart SA is delighted to announce completion of enrollment in its U.S. IDE trial studying the BAGUERA®C Cervical Disc Prosthesis in patients with single-level cervical disc disease between C3 to C7 compared to a commercially marketed cervical disc implant.

Centinel Spine®, LLC, a leading global medical device company addressing cervical and lumbar spinal disease through anterior surgical access, today announced U.S. Food and Drug Administration (FDA) Pre-Market Application (PMA) Approval for 1-level indications for three additional cervical total disc replacement (TDR) devices: prodisc C Vivo, prodisc C Nova, and prodisc C SK.

Armen Khachatryan, MD and The Disc Replacement Center announced successful completion of the first series of MOTUS lumbar total joint replacement surgeries as part of the BalancedBack pivotal clinical trial sponsored by 3Spine.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), today announced 36-month follow-up results from the 404-patient Phase 3 trial of its allogeneic cell therapy rexlemestrocel-L (MPC-06-ID) in patients with chronic low back pain (CLBP) associated with degenerative disc disease (DDD).